Trans-conjunctival Erosion of a Novel SIBS Microshunt After Revision Surgery Using Mitomycin C

Luke Michaels1, Lee Holland1, Karl Mercieca1,2

  • 1Manchester Royal Eye Hospital, Manchester, UK.

Journal of Glaucoma
|April 4, 2021
PubMed

Insights

This case report details the first instance of trans-conjunctival Preserflo microshunt erosion following revision surgery with mitomycin C. To prevent this, surgeons should remove the initial microshunt and use mitomycin C sparingly in secondary procedures.

Area of Science:

  • Ophthalmology
  • Surgical Innovation

Background:

  • Glaucoma surgeries aim to reduce intraocular pressure.
  • Preserflo microshunt is a device used in glaucoma surgery.
  • Revision surgeries may be necessary for suboptimal outcomes.

Purpose of the Study:

  • To report the first case of trans-conjunctival Preserflo microshunt erosion.
  • To identify risk factors and propose preventative measures for this complication.

Main Methods:

  • Case report of a patient undergoing revision glaucoma surgery.
  • Detailed description of surgical technique and intraoperative findings.
  • Histopathological examination of the eroded microshunt.

Main Results:

  • The patient experienced trans-conjunctival Preserflo microshunt erosion post-revision surgery.
  • Mitomycin C was used during the revision procedure.
  • Erosion occurred at the site of the original microshunt.

Conclusions:

  • Revision glaucoma surgery with mitomycin C carries a risk of microshunt erosion.
  • Complete removal of the prior microshunt is recommended before revision.
  • Judicious use of mitomycin C in secondary procedures may mitigate this risk.